Zinforo®: Simple twice-daily dosing1
No dosage adjustment required for most elderly patients or those with concurrent comorbidities1
Dosage in adults aged 18 years and older1
600 mg IV (over 5-60 minutes) every 12 hours
5-14 days for cSSTI
Dosage adjustments are required in patients with moderate-to-severe (CrCl ≥15 to ≤50 mL/min) renal impairment and ESRD, including patients undergoing haemodialysis.1
cSSTI: complicated skin and soft tissue infections; CrCl: creatinine clearance; ESRD: end-stage renal disease; IV: intravenous
- ZINFORO® (ceftaroline fosamil). Local Product Document of Ceftaroline; LPDZIN 072021.
Zinforo® dosing in renal impairment1
*Applies only for standard dose regimens in adults and paediatric patients aged ≥2 months, including patients with renal impairment. For patients with supranormal renal clearance receiving the standard dose, an infusion time of 60 minutes may be preferable. Prolonging the infusion duration may also help to manage infusion-related reactions (e.g. phlebitis).1
*Calculated using the Cockroft-Gault formula.1
†Dose is based on CrCl . CrCl should be closely monitored and the dose adjusted according to changing renal function.1
‡Infusion times of <60 minutes and high-dose recommendations are based on PK/PD analyses only.1
§ZINFORO® is haemodialysable , therefore ZINFORO® should be administered after haemodialysis on haemodialysis days.
IIFor treatment of S. aureus for which the ZINFORO® MIC is ≤1 mg/L, the standard dose is recommended.1
CAP, community acquired pneumonia; CrCl, creatinine clearance; cSSTI, complicated skin and soft tissue infection; ESRD, end-stage renal disease; MIC, minimum inhibitory concentration; PD, pharmacodynamic; PK, pharmacokinetic.
- ZINFORO® (ceftaroline fosamil) Local Product Document of Ceftaroline LPDZIN 072021.
PP-ZFO-IND-0279. 09 December 2021
Please click on Prescribing Information link to view safety and adverse events information of Zinforo.
For the use only of registered medical practitioner, or a hospital or a laboratory.